Search
News & Events
30% of children at risk of future heart diseaseAlmost 30% of 14-year-old Australian children fall within a group identified as being at future increased risk of heart disease, type 2 diabetes or stroke
Research
Disparities in Diabetes Technology Uptake in Youth and Young Adults With Type 1 Diabetes: A Global PerspectiveGlobally, nearly 9 million people are living with type 1 diabetes (T1D). Although the incidence of T1D is not affected by socioeconomic status, the development of complications and limited access to modern therapy is overrepresented in vulnerable populations. Diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, are considered the gold standard for management of T1D, yet access to these technologies varies widely across countries and regions, and varies widely even within high-income countries.
Research
Real-world glycaemic outcomes in children and young people on advanced hybrid closed-loop therapy: A population-based study in Western AustraliaTo evaluate real-world glycaemic outcomes in children with type 1 diabetes commencing advanced hybrid closed loop therapy and to explore these outcomes based on the cohort's clinical and socioeconomic characteristics.
Research
Priority setting: Development of the South Australian Aboriginal Chronic Disease Consortium RoadMap for ActionAboriginal and Torres Strait Islander (Aboriginal) people in South Australia are overburdened by cardiovascular disease, diabetes and cancer. The South Australian Aboriginal Chronic Disease Consortium (Consortium) was established in June 2017 as a collaborative partnership to lead the implementation of three state-wide chronic disease plans using a strategic approach to identifying key priority areas for action.
Research
Short-Term Diabetic Retinopathy Status in People with Type 1 Diabetes Commencing Automated Insulin DeliveryRapid improvements in glucose control may lead to early worsening of diabetic retinopathy (EWDR). There is a need to demonstrate safety in people commencing automated insulin delivery (AID) due to the known efficacy in rapid glycemic improvement. We aimed to investigate short-term DR outcomes in people (aged ≥13 years) with type 1 diabetes after initiation of AID (use ≥6 months).
Research
Reproducibility of plasma glucose responses to moderate-intensity exercise in individuals with type 1 diabetesTo examine the within-person variability in plasma glucose responses to moderate-intensity morning exercise in young individuals with type 1 diabetes after overnight fasting and under basal insulin conditions.
Research
Efficacy of the MiniMed™ 670G hybrid closed loop system in managing postprandial glucose excursion with high protein high fat foods in children and adolescents under free-living conditionsHigh protein high fat meals are considered “difficult” foods because they can cause prolonged hyperglycemia after ingestion. The potential of hybrid closed loop therapy in managing postprandial glucose excursions with these difficult foods remains unknown. This pilot study aimed to explore the impact of manual mode in standard insulin pump therapy and auto mode with hybrid closed loop pump therapy in managing glucose excursions caused by HPHF foods and to obtain feedback from families about each mode.
Research
Role of HLA-DQ typing and anti-tissue transglutaminase antibody titers in diagnosing celiac disease without duodenal biopsy in type 1 diabetesHLA-DQ typing is not cost effective as a first-line screening test for CD in T1D patients because of over-representation of CD permissive HLA alleles in this group
Research
Performance of medtronic hybrid closed-loop iterations: Results from a randomized trial in adolescents with type 1 diabetesThis study investigates the performance of an iteration of the Medtronic hybrid closed-loop algorithm
Research
Insulin Pump Therapy in Adolescents With Very Poor Glycemic Control During a 12-Month Cohort TrialWe conclude that insulin pump therapy can be an effective tool to improve glycemic control in adolescents with long-standing treatment resistance